Prevention of metabolic syndrome and anti-aging potential of walnut in middle-aged and elderly people. Other
Conditions
Interventions
Two intervention periods of 28 days each, separated by a one-month (31 days) washout period. Participants were randomly assigned to receive either a daily serving of walnut kernels (45 g per day) or h
Sponsors
University of Medicine and Pharmacy "Iuliu Ha?ieganu" Cluj-Napoca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Caucasian adults, women and men aged 40-65 years 2. With no known allergy to walnuts 3. Provide informed consent 4. Clinical characteristics: healthy individuals at MetS risk with at least one of the specific parameters present, including: 4.1. Abdominal obesity: waist circumference (WC) = 102 cm and = 88 cm for European men and women, respectively 4.2. Hypertension: systolic blood pressure (SBP) = 130 mmHg or/and diastolic blood pressure (DBP) = 85 mmHg 4.3. Dyslipidemia: TG = 150 mg/dL and high-density lipoprotein cholesterol (HDL-c) < 40 mg/dL in men or < 50 mg/dL in women 4.4. Dysglycemia: fasting blood glucose (FBG) = 100 mg/dL
Exclusion criteria
Exclusion criteria: 1. Individuals with allergies to walnuts, other tree nuts, and peanuts or following restric-tive diets for food allergies, food intolerances (lactose, fructose, gluten) 2. Diets for chronic gastrointestinal or kidney disease, vegetarians, or other types of diet that could interfere with study results, as well as those with current or recent eating disorders (last 6 months prior to the start of the study). 3. Individuals with current chronic diseases: chronic intestinal diseases (ulcerative colitis, Crohn's disease), chronic renal disease, CVD, pulmonary disease, Type 1 or 2 diabetes, cancer, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), gallbladder disorders (gallbladder lithiasis, biliary dyskinesia, and acute or chronic cholecystitis) 4. Drug treatments (insulin therapy, hypoglycemic and/or hypolipidemic treatments, chronic treatment with non-steroidal and/or steroidal an-ti-inflammatory drugs) 5. Concomitant use or at least two weeks prior to the start of the study of dietary supplements (vitamins or minerals, anti-inflammatory and/or antiox-idant compounds, including fish oil, omega-3 fatty acids, resveratrol, curcumin, vita-min C, selenium, zinc, as well as dietary fiber, probiotics, symbiotics). 6. Pregnancy 7. Smoking 8. Chronic alcohol consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of blood vascular cell adhesion molecule (s-VCAM) levels using Elisa Kit at baseline and at the end of each intervention period. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Blood biomarkers of oxidative stress (CAT, GPx, TAC) measured at baseline and at the other three-monthly scheduled clinic visits using ELISA kits. 2. Blood biomarkers of inflammation (IL-6, IL-8, IL-1, TNF-alpha) measured at baseline and at the other three-monthly scheduled clinic visits using ELISA kits. 3. Blood pressure values (SBP, DBP) measured at baseline and at the other three-monthly scheduled clinic visits using a professional automated sphygmomanometer. 4. Blood lipid profile markers (TG, TC, HDL-C, LDL-C) measured at baseline and at the other three-monthly scheduled clinic visits using standard laboratory methods. 5. Blood glucose profile (basal blood glucose, HbA1c) measured at baseline and at the other scheduled three-monthly clinic visits using standard laboratory methods. 6. Anthropometric parameters: body height (BH), waist circumference (WC), hip circumference (HC), waist-to-hip circumference ratio (WHR), body weight (BW), body mass index (BMI), body fat mass (BFM), and body water (BW), measured at baseline and at the other three-monthly scheduled clinic visits using a professional segmental body composition scale and a taliometer. | — |
Countries
Romania
Contacts
Public ContactLetitia Mates
Outcome results
None listed